company background image
1332

Touyun Biotech GroupSEHK:1332 Stock Report

Market Cap

HK$2.5b

7D

10.0%

1Y

79.6%

Updated

23 Oct, 2021

Data

Company Financials
1332 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

1332 Overview

Touyun Biotech Group Limited, an investment holding company, designs, develops, manufactures, and sells packaging products in Hong Kong, the People’s Republic of China, Europe, North and South America, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Touyun Biotech Group
Historical stock prices
Current Share PriceHK$0.88
52 Week HighHK$0.47
52 Week LowHK$1.75
Beta-1.17
1 Month Change-2.22%
3 Month Change-3.30%
1 Year Change79.59%
3 Year Change292.86%
5 Year Change-24.14%
Change since IPO287.32%

Recent News & Updates

Mar 12
Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?

Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?

The big shareholder groups in China Touyun Tech Group Limited ( HKG:1332 ) have power over the company. Large companies...

Jan 15
If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns

If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...

Shareholder Returns

1332HK PackagingHK Market
7D10.0%1.5%2.1%
1Y79.6%6.6%5.9%

Return vs Industry: 1332 exceeded the Hong Kong Packaging industry which returned 6.6% over the past year.

Return vs Market: 1332 exceeded the Hong Kong Market which returned 5.9% over the past year.

Price Volatility

Is 1332's price volatile compared to industry and market?
1332 volatility
1332 Beta-1.17
Industry Beta0.71
Market Beta1

Stable Share Price: 1332 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 1332's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1989506n/ahttps://touyunbiotech.com.hk

Touyun Biotech Group Limited, an investment holding company, designs, develops, manufactures, and sells packaging products in Hong Kong, the People’s Republic of China, Europe, North and South America, and internationally. It operates through four segments: QR Code Business, Packaging Products, Treasury Investment, and Chlamydomonas Reinhardtii Product Business. The QR Code Business segment provides QR codes on product packaging and solutions; and online advertising display services.

Touyun Biotech Group Fundamentals Summary

How do Touyun Biotech Group's earnings and revenue compare to its market cap?
1332 fundamental statistics
Market CapHK$2.47b
Earnings (TTM)-HK$147.93m
Revenue (TTM)HK$252.18m

9.8x

P/S Ratio

-16.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1332 income statement (TTM)
RevenueHK$252.18m
Cost of RevenueHK$146.36m
Gross ProfitHK$105.82m
ExpensesHK$253.75m
Earnings-HK$147.93m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.053
Gross Margin41.96%
Net Profit Margin-58.66%
Debt/Equity Ratio60.6%

How did 1332 perform over the long term?

See historical performance and comparison

Valuation

Is Touyun Biotech Group undervalued compared to its fair value and its price relative to the market?

5.32x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1332's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1332's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1332 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Packaging industry average.

PE vs Market: 1332 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1332's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1332 is overvalued based on its PB Ratio (5.3x) compared to the HK Packaging industry average (0.6x).


Future Growth

How is Touyun Biotech Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

31.6%

Forecasted Materials industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Touyun Biotech Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Touyun Biotech Group performed over the past 5 years?

38.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1332 is currently unprofitable.

Growing Profit Margin: 1332 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1332 is unprofitable, but has reduced losses over the past 5 years at a rate of 38.9% per year.

Accelerating Growth: Unable to compare 1332's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1332 is unprofitable, making it difficult to compare its past year earnings growth to the Packaging industry (31.8%).


Return on Equity

High ROE: 1332 has a negative Return on Equity (-26.05%), as it is currently unprofitable.


Financial Health

How is Touyun Biotech Group's financial position?


Financial Position Analysis

Short Term Liabilities: 1332's short term assets (HK$540.0M) exceed its short term liabilities (HK$511.5M).

Long Term Liabilities: 1332's short term assets (HK$540.0M) exceed its long term liabilities (HK$6.1M).


Debt to Equity History and Analysis

Debt Level: 1332's debt to equity ratio (60.6%) is considered high.

Reducing Debt: 1332's debt to equity ratio has increased from 0.01% to 60.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1332 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 1332 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9% each year


Dividend

What is Touyun Biotech Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1332's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1332's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1332's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1332's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1332's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average board tenure


CEO

Touyun Biotech Group has no CEO, or we have no data on them.


Board Members

Experienced Board: 1332's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Touyun Biotech Group Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Touyun Biotech Group Limited
  • Ticker: 1332
  • Exchange: SEHK
  • Founded: 1989
  • Industry: Paper Packaging
  • Sector: Materials
  • Market Cap: HK$2.467b
  • Shares outstanding: 2.80b
  • Website: https://touyunbiotech.com.hk

Number of Employees


Location

  • Touyun Biotech Group Limited
  • Kwan Chart Tower
  • 12th Floor
  • Wan Chai
  • Hong Kong

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/23 10:03
End of Day Share Price2021/10/22 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.